Scotiabank Begins Coverage on Liquidia (NASDAQ:LQDA)

Scotiabank initiated coverage on shares of Liquidia (NASDAQ:LQDA - Free Report) in a research note published on Wednesday, Marketbeat.com reports. The brokerage issued a sector outperform rating and a $30.00 price objective on the stock.

LQDA has been the topic of several other reports. Raymond James upgraded shares of Liquidia from an "outperform" rating to a "strong-buy" rating in a report on Monday, August 19th. HC Wainwright cut their price target on shares of Liquidia from $32.00 to $29.00 and set a "buy" rating on the stock in a report on Tuesday, August 20th. Needham & Company LLC reaffirmed a "buy" rating and set a $25.00 price target on shares of Liquidia in a research report on Monday, August 19th. Lifesci Capital initiated coverage on Liquidia in a report on Thursday, October 3rd. They set an "outperform" rating and a $30.00 price objective for the company. Finally, Oppenheimer assumed coverage on Liquidia in a research note on Tuesday, June 25th. They set a "market perform" rating on the stock. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, Liquidia presently has an average rating of "Moderate Buy" and an average target price of $24.67.

Liquidia Stock Up 2.2 %

LQDA traded up $0.25 during trading hours on Wednesday, reaching $11.63. 1,272,987 shares of the company's stock traded hands, compared to its average volume of 1,006,331. The firm has a 50-day moving average price of $10.40 and a 200 day moving average price of $11.97. The firm has a market capitalization of $888.69 million, a PE ratio of -7.41 and a beta of 0.22. Liquidia has a 52-week low of $5.71 and a 52-week high of $16.99.

Liquidia (NASDAQ:LQDA - Get Free Report) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.02). The firm had revenue of $3.66 million during the quarter, compared to the consensus estimate of $7.92 million. Liquidia had a negative return on equity of 183.57% and a negative net margin of 755.46%. Equities analysts predict that Liquidia will post -1.69 EPS for the current fiscal year.

Insiders Place Their Bets

In other Liquidia news, Director Caligan Partners Lp purchased 150,000 shares of Liquidia stock in a transaction on Friday, August 30th. The stock was bought at an average cost of $9.51 per share, with a total value of $1,426,500.00. Following the transaction, the director now owns 6,994,997 shares of the company's stock, valued at $66,522,421.47. This represents a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Liquidia news, CFO Michael Kaseta sold 3,892 shares of the stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $11.11, for a total transaction of $43,240.12. Following the transaction, the chief financial officer now owns 311,076 shares in the company, valued at approximately $3,456,054.36. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Caligan Partners Lp acquired 150,000 shares of the business's stock in a transaction dated Friday, August 30th. The stock was acquired at an average price of $9.51 per share, with a total value of $1,426,500.00. Following the completion of the transaction, the director now directly owns 6,994,997 shares of the company's stock, valued at approximately $66,522,421.47. This represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders sold 22,731 shares of company stock valued at $249,571. 31.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On Liquidia

A number of institutional investors have recently added to or reduced their stakes in the stock. Patient Square Capital LP purchased a new stake in Liquidia during the 1st quarter worth approximately $105,942,000. Farallon Capital Management LLC acquired a new position in Liquidia during the first quarter worth $30,311,000. Sapient Capital LLC acquired a new stake in shares of Liquidia in the 3rd quarter worth $1,336,000. BNP Paribas Financial Markets raised its holdings in shares of Liquidia by 119.4% during the 1st quarter. BNP Paribas Financial Markets now owns 230,248 shares of the company's stock worth $3,396,000 after acquiring an additional 125,315 shares during the period. Finally, HighVista Strategies LLC acquired a new position in shares of Liquidia during the 2nd quarter valued at about $1,461,000. Institutional investors and hedge funds own 64.54% of the company's stock.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).